<span data-sheets-value="[null,2,"Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon."]" data-sheets-userformat="[null,null,641,[null,1],null,null,null,null,null,null,0,null,0]">Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

Immunotherapy for First Line Therapy of Advanced NSCLC

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers.  The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Science

Medicine

Health & Fitness

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit CancerGRACE.org for more info.

Share Immunotherapy for First Line Therapy of Advanced NSCLC

Sign up to save your podcasts

Immunotherapy for First Line Therapy of Advanced NSCLC

Immunotherapy for First Line Therapy of Advanced NSCLC